Manufacturers announce positive results for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution in phase III study in cataplexy or excessive daytime sleepiness with narcolepsy

In the study, Xywav, anoxybate product with 92% less sodium than sodium oxybate (1g less at the recommended dose of 6g per night), provided significant improvements in the weekly number of cataplexy attacks and Epworth Sleepiness Scale scores vs placebo.

Biospace Inc.